Literature DB >> 20427081

Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Albert Adam1, Nicolas Montpas, David Keire, Anik Désormeaux, Nancy J Brown, François Marceau, Benjamin Westenberger.   

Abstract

UNLABELLED: Oversulfated chondroitin sulfate (OSCS) contaminated heparin has been associated with severe anaphylactoid reaction (AR), mainly in dialysed patients. Although attributed to bradykinin (BK) released during contact system activation by OSCS, no definitive evidence exists until now for a BK release during incubation of contaminated heparin with human plasma. In this study, we investigated the kinin forming capacity of OSCS and OSCS contaminated heparin when incubated in vitro with a pool of human plasma. At 100 microg/mL, OSCS liberates BK in a profile similar but not identical to dextran sulfate, a well known activator of the plasma contact system. The results have highlighted that the quantity of BK accumulated during contact system activation depends not only on the concentration of OSCS but also on the plasma dilution and the presence of an angiotensin converting enzyme inhibitor. We demonstrate a highly significant correlation between the concentration of OSCS present in the contaminated heparin and BK released concentration. In conclusion, for the first time, we show that OSCS contaminated heparin incubated with human plasma has the capacity to liberate BK at a concentration that could explain the role of this inflammatory peptide in the pathophysiology of AR associated with OSCS contaminated heparin. DISCLAIMER: The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427081      PMCID: PMC2896062          DOI: 10.1016/j.biomaterials.2010.03.074

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  36 in total

1.  Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.

Authors:  D Pruneau; J L Paquet; J M Luccarini; E Defrêne; C Fouchet; R M Franck; B Loillier; C Robert; P Bélichard; H Duclos; B Cremers; P Dodey
Journal:  Immunopharmacology       Date:  1999-09

2.  The FDA and safety--beyond the heparin crisis.

Authors:  Cato T Laurencin; Lakshmi Nair
Journal:  Nat Biotechnol       Date:  2008-06       Impact factor: 54.908

3.  Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.

Authors:  M Cyr; Y Lepage; C Blais; N Gervais; M Cugno; J L Rouleau; A Adam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-07       Impact factor: 4.733

4.  Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates.

Authors:  D R Bachvarov; S Houle; M Bachvarova; J Bouthillier; A Adam; F Marceau
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

5.  Absence of ligand-induced regulation of kinin receptor expression in the rabbit.

Authors:  T Sabourin; K Guay; S Houle; J Bouthillier; D R Bachvarov; A Adam; F Marceau
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.

Authors:  David A Keire; Michael L Trehy; John C Reepmeyer; Richard E Kolinski; Wei Ye; Jamie Dunn; Benjamin J Westenberger; Lucinda F Buhse
Journal:  J Pharm Biomed Anal       Date:  2009-10-30       Impact factor: 3.935

7.  Outbreak of adverse reactions associated with contaminated heparin.

Authors:  David B Blossom; Alexander J Kallen; Priti R Patel; Alexis Elward; Luke Robinson; Ganpan Gao; Robert Langer; Kiran M Perkins; Jennifer L Jaeger; Katie M Kurkjian; Marilyn Jones; Sarah F Schillie; Nadine Shehab; Daniel Ketterer; Ganesh Venkataraman; Takashi Kei Kishimoto; Zachary Shriver; Ann W McMahon; K Frank Austen; Steven Kozlowski; Arjun Srinivasan; George Turabelidze; Carolyn V Gould; Matthew J Arduino; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-12-03       Impact factor: 91.245

8.  Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate.

Authors:  Yaneth E Carranza; Clarissa Durand-Rougley; Vasant Doctor
Journal:  Blood Coagul Fibrinolysis       Date:  2008-09       Impact factor: 1.276

Review 9.  Lessons learned from the contamination of heparin.

Authors:  Haiying Liu; Zhenqing Zhang; Robert J Linhardt
Journal:  Nat Prod Rep       Date:  2009-01-19       Impact factor: 13.423

10.  Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.

Authors:  Michael L Trehy; John C Reepmeyer; Richard E Kolinski; Benjamin J Westenberger; Lucinda F Buhse
Journal:  J Pharm Biomed Anal       Date:  2008-12-24       Impact factor: 3.935

View more
  8 in total

Review 1.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

2.  Mass balance analysis of contaminated heparin product.

Authors:  Zhenling Liu; Zhongping Xiao; Sayaka Masuko; Wenjing Zhao; Eric Sterner; Vinod Bansal; Jawed Fareed; Jonathan Dordick; Fuming Zhang; Robert J Linhardt
Journal:  Anal Biochem       Date:  2010-09-17       Impact factor: 3.365

Review 3.  Analysis and characterization of heparin impurities.

Authors:  Szabolcs Beni; John F K Limtiaco; Cynthia K Larive
Journal:  Anal Bioanal Chem       Date:  2010-09-03       Impact factor: 4.142

4.  Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events.

Authors:  Zhao-Hua Zhou; Trina Chen; Kamalpreet Arora; Kenneth Hyams; Steven Kozlowski
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

5.  The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.

Authors:  J Hogwood; A Naggi; G Torri; C Page; P Rigsby; B Mulloy; E Gray
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

6.  Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.

Authors:  Zhao-Hua Zhou; Mohsen Rajabi; Trina Chen; Elena Karnaukhova; Steven Kozlowski
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

7.  The Toxicology of Native Fucosylated Glycosaminoglycans and the Safety of Their Depolymerized Products as Anticoagulants.

Authors:  Lisha Lin; Sujuan Li; Na Gao; Weili Wang; Taocui Zhang; Lian Yang; Xingzhi Yang; Dan Luo; Xu Ji; Jinhua Zhao
Journal:  Mar Drugs       Date:  2021-08-27       Impact factor: 5.118

8.  Rediscovery of a forgotten disease: Hereditary Angioedema.

Authors:  Okan Gülbahar; Anastasios E Germenis
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.